证券代码：300030 证券简称：阳普医疗 公告编号：2025-045 阳普医疗科技股份有限公司 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 特此公告。 阳普医疗科技股份有限公司监事会 2025 年 10 月 27 日 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 阳普医疗科技股份有限公司（以下简称"公司"）第六届监事会第十四次会 议（以下简称"本次会议"）通知已于 2025 年 10 月 20 日以电子邮件方式送达全 体监事。本次会议于 2025 年 10 月 27 日在公司会议室以现场与通讯相结合的方式 召开。本次会议应到监事 3 人，实到监事 3 人，公司高级管理人员列席了本次会 议。本次会议的内容以及召集、召开的方式、程序均符合《公司法》和《公司章 程》的规定。本次会议由监事会主席方秋鹏先生主持。与会监事经过充分的讨论， 通过以下决议： 一、审议通过《2025 年第三季度报告》 公司监事会在全面审核和了解公司 2025 年第三季度报告后，认为公司 2025 年第三季度报告真实、准确、完整地反映了公司的实际经营状况和经营成果，认 为其陈 ...

证券代码：300030 证券简称：阳普医疗 公告编号：2025-044 阳普医疗科技股份有限公司 第六届董事会第十六次会议决议公告 2025 年 10 月 27 日 公司董事会在全面审核和了解公司 2025 年第三季度报告后，认为公司 2025 年第三季度报告真实、准确、完整地反映了公司的实际经营状况和经营成果，认 为其陈述事项真实、准确、完整，不存在应披露而未披露事项，不存在任何虚假 记载、误导性陈述或者重大遗漏。 《2025 年第三季度报告》（公告编号：2025-047）详见中国证监会指定的创 业板信息披露网站巨潮资讯网。 本议案提交董事会审议前已经公司董事会审计委员会审议通过。 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 特此公告。 阳普医疗科技股份有限公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 阳普医疗科技股份有限公司（以下简称"公司"）第六届董事会第十六次会 议（以下简称"本次会议"）通知已于 2025 年 10 月 20 日以电子邮件方式送达全 体董事。本次会议于 2025 年 10 月 27 日在公司会议室以现场与 ...

Financial Performance - Q3 2025 revenue was CNY 118,274,679.35, a decrease of 7.82% year-over-year, while year-to-date revenue reached CNY 349,231,193.17, down 17.14% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2025 was CNY 8,777,532.54, an increase of 123.57% year-over-year, with year-to-date net profit at CNY 24,044,095.67, up 156.55%[5] - The net profit excluding non-recurring items for Q3 2025 was CNY 15,177,917.20, a significant increase of 423.96% year-over-year, while year-to-date it was CNY 30,357,702.81, up 325.04%[5] - Total operating revenue for Q3 2025 was CNY 349,231,193.17, a decrease of 17.1% from CNY 421,468,424.66 in the same period last year[29] - Total operating costs for Q3 2025 were CNY 329,782,171.95, down 20.4% from CNY 413,928,591.21 in the previous year[29] - Net profit for Q3 2025 was CNY 23,445,300.50, compared to a net loss of CNY 44,632,335.57 in Q3 2024[30] - The company reported a gross profit margin of approximately 5.5% in Q3 2025, compared to a negative margin in the same quarter last year[30] Cash Flow and Assets - Cash flow from operating activities for the year-to-date period was CNY 71,345,913.50, an increase of 66.73%[5] - Cash flow from operating activities decreased by 45.21% to ¥5,479,561.18, due to a reduction in government subsidies and project guarantee recoveries[15] - Cash flow from investing activities showed a net outflow of ¥44,586,782.84, a significant increase of 276.57% compared to the previous period[16] - Cash and cash equivalents decreased by 1,765.19% to -¥130,310,349.72, primarily due to repayment of bank loans using internal funds[16] - The company's cash and cash equivalents decreased from CNY 247,949,011.09 to CNY 117,638,671.25, representing a decline of approximately 52.6%[27] - The ending balance of cash and cash equivalents was $117,020,731.28, down from $219,220,309.59[33] Investments and Income - The company recognized an investment income increase of CNY 31,291,100.00 from Shenzhen Yanghe Biomedical Industry Investment Co., Ltd. compared to the previous year[10] - Investment income increased by 244.16% to ¥18,710,906.35, reflecting a rise in fair value confirmation of investments[14] - Total profit rose by 167.56% to ¥27,926,751.64, driven by increased investment income and reduced losses from fair value changes of associates[14] - Cash received from investment income was $24,692,839.59, significantly higher than $1,614,986.41 in the previous period[33] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,504, with no preferred shareholders having restored voting rights[18] - The largest shareholder, Deng Guanhua, holds 15.91% of shares, with 36,895,916 shares pledged[18] - The total number of restricted shares decreased from 49,194,555 to 36,895,916 due to the release of shares held by executives[20] Cost Management and Efficiency - The company plans to continue focusing on cost control and efficiency improvements to mitigate the impact of declining revenues[10] - The company closed its wholly-owned subsidiary Guangzhou Ruida Medical Equipment Co., Ltd. as part of cost reduction efforts[23] - Financial expenses for the year-to-date period were CNY 3,213,416.02, down 58.46% compared to the previous year, primarily due to reduced interest expenses[13] Research and Development - The company has made significant investments in R&D to enhance product offerings and market competitiveness[22] - Research and development expenses for Q3 2025 were CNY 17,942,654.55, down 23.2% from CNY 23,376,301.59 in the same quarter last year[29] Asset Management - Total assets as of September 30, 2025, were CNY 1,079,746,419.77, a decrease of 13.21% from the end of the previous year[5] - The total assets decreased to CNY 1,079,746,419.77 from CNY 1,244,146,915.63, reflecting a decline of 13.2% year-over-year[29] - Total liabilities decreased to CNY 415,452,132.33 from CNY 600,282,029.67, a reduction of 30.7% compared to the previous year[29] - The company reported a total non-current asset balance of CNY 1,200,000,000.00 as of the end of the reporting period[27] Business Development - The company has established a joint venture named "联合生命" focusing on cell therapy and high-end health management, with operations commencing in the Hengqin area[25] - The company participated in several high-profile academic exchanges and exhibitions, showcasing key products like the specimen management system and intelligent blood collection management system[22] - The company aims to expand its localized service network, receiving high recognition from industry peers during recent conferences[22]

Core Viewpoint - Yangpu Medical's stock price has shown a significant increase of 42.21% year-to-date, indicating strong market performance despite recent fluctuations [2]. Company Overview - Yangpu Medical Technology Co., Ltd. was established on August 19, 1996, and listed on December 25, 2009. The company is located in Zhuhai, Guangdong Province, and primarily provides technical solutions, products, and services for clinical testing laboratories and clinical care [2]. - The company's revenue composition includes: vacuum blood collection systems (66.48%), reagents (12.23%), software products and services (10.03%), testing services (5.10%), other products (3.23%), instruments (2.81%), and microbiological transport systems (0.12%) [2]. Stock Performance - As of October 21, Yangpu Medical's stock price reached 7.85 CNY per share, with a trading volume of 28.23 million CNY and a turnover rate of 1.34%, resulting in a total market capitalization of 2.43 billion CNY [1]. - The stock has experienced a net inflow of 527,800 CNY from main funds, with large orders accounting for 10.60% of purchases and 8.73% of sales [1]. Financial Performance - For the first half of 2025, Yangpu Medical reported a revenue of 231 million CNY, a year-on-year decrease of 21.22%. However, the net profit attributable to shareholders increased by 389.40% to 15.27 million CNY [2]. - The company has not distributed any dividends in the past three years, with a total payout of 79.13 million CNY since its A-share listing [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 5.76% to 24,400, with an average of 11,149 circulating shares per person, an increase of 11.13% [2]. - Notable institutional holdings include Huaxia CSI 500 Index Enhanced A (007994) as the fifth largest shareholder, increasing its stake by 3.60 million shares, and new entrants such as Huaxia Zhisheng Pioneer Stock (LOF) A (501219) and Huaxia CSI 500 Index Smart Enhanced A (013233) [3].

Group 1 - Yangpu Medical announced the appointment of Zhou Wei as the new deputy general manager, based on the recommendation of the controlling shareholder Zhuhai Gree Financial Investment Management Co., Ltd. and the nomination by the acting general manager Jiang Guangcheng [1] - For the fiscal year 2024, Yangpu Medical's revenue composition is 99.18% from industrial operations and 0.82% from financial leasing [1] - The current market capitalization of Yangpu Medical is 2.4 billion yuan [2] Group 2 - The competition between Farmer and Yibao has intensified, with Farmer's green bottle launch leading to a significant market share decline for Yibao, dropping nearly 5 percentage points [2]

一、审议通过《关于聘任周伟为公司副总经理的议案》 第六届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 阳普医疗科技股份有限公司（以下简称"公司"）第六届董事会第十五次会 议（以下简称"本次会议"）通知已于 2025 年 9 月 22 日以电子邮件方式送达全 体董事。本次会议于 2025 年 9 月 29 日在公司会议室以现场与通讯相结合的方式 召开。本次会议应到董事 9 人，实到董事 9 人，公司监事和高级管理人员列席了 本次会议。本次会议的内容以及召集、召开的方式、程序均符合《公司法》和《公 司章程》的规定。本次会议由董事长杨涛先生主持。与会董事经过充分的讨论， 通过以下决议： 公司董事会同意聘任周伟先生为公司副总经理，任期自本次董事会审议通过 之日起至公司第六届董事会任期届满之日止。 具体内容详见公司同日在中国证监会指定的创业板信息披露网站巨潮资讯网 披露的《关于聘任高级管理人员的公告》（公告编号：2025-043）。 证券代码：300030 证券简称：阳普医疗 公告编号：2025-042 阳普医疗科技股份有限公司 表决结果： ...

关于聘任高级管理人员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 9 月 29 日，阳普医疗科技股份有限公司（以下简称"公司"）召开 了第六届董事会第十五次会议，审议通过了《关于聘任周伟为公司副总经理的议 案》，具体情况如下： 基于公司发展及实际工作需要，经公司控股股东珠海格力金融投资管理有限 公司推荐，代理总经理蒋广成先生提名、董事会提名委员会审核，董事会决定聘 任周伟先生担任公司副总经理，任期自第六届董事会第十五次会议通过之日起至 第六届董事会届满之日止。 周伟先生具备担任公司副总经理的履职能力和任职资格，符合《中华人民共 和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等法律法规、规范性文件以及《公司章程》的规定。 证券代码：300030 证券简称：阳普医疗 公告编号：2025-043 周伟先生简历详见附件。 特此公告。 阳普医疗科技股份有限公司 附件： 周伟先生简历 周伟先生，1979 年 1 月出生，本科学历，无境外永久居留权。2000 年 7 月 至 2011 年 12 月在新华社工作 ...

Group 1 - The core point of the news is that Yangpu Medical's stock has experienced a decline of 5.03% on September 23, with a total market value of 2.279 billion yuan and a trading volume of 36.18 million yuan, indicating a continuous downward trend over three days with a cumulative drop of 5.02% [1] - Yangpu Medical, established on August 19, 1996, and listed on December 25, 2009, is based in Zhuhai, Guangdong Province. The company specializes in providing technical solutions, products, and services for clinical testing laboratories and clinical care [1] - The main revenue composition of Yangpu Medical includes: vacuum blood collection systems (66.48%), reagents (12.23%), software products and services (10.03%), testing services (5.10%), other products (3.23%), instruments (2.81%), and microbiological transport systems (0.12%) [1] Group 2 - From the perspective of major fund holdings, Penghua Fund has one fund heavily invested in Yangpu Medical. The Penghua Smart Investment Digital Economy Mixed A Fund (020086) reduced its holdings by 31,800 shares in the second quarter, now holding 21,100 shares, which accounts for 0.62% of the fund's net value [2] - The fund has incurred a floating loss of approximately 8,229 yuan today, with a total floating loss of 8,651 yuan during the three-day decline [2] - The Penghua Smart Investment Digital Economy Mixed A Fund (020086) was established on May 17, 2024, with a latest scale of 5.1349 million yuan. Year-to-date returns are 44.8%, ranking 1,390 out of 8,172 in its category, while the one-year return is 100.02%, ranking 638 out of 7,995 [2]

Group 1: Company Governance - The board of directors consists of 9 members, with 3 from Zhuhai Gree Jin控 and 3 from the original company. In case of a tie (3:3), decisions are made based on a majority vote of all directors [2] - Board resolutions require a majority approval from all directors as per the company's articles of association [2] Group 2: Investor Relations Activities - The company participated in the "2025 Guangdong District Investor Reception Day" on September 19, 2025, from 15:30 to 17:00, via the "Panorama Roadshow" website [1] - The event aimed to enhance interaction and communication with investors regarding the company's operational status and other investor concerns [1] Group 3: Information Disclosure - The company adheres strictly to relevant laws and regulations regarding information disclosure and has no undisclosed information that should have been revealed [3]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300030 证券简称：阳普医疗 公告编号：2025-041 阳普医疗科技股份有限公司 关于参加2025年广东辖区投资者网上集体接待日活动的公告 阳普医疗科技股份有限公司董事会 2025 年 9 月 17 日 为进一步加强与投资者的互动交流，阳普医疗科技股份有限公司（以下简称 "公司"）将参加由广东证监局、广东上市公司协会联合举办的"向新提质 价 值领航——2025 年广东辖区投资者集体接待日暨辖区上市公司中报业绩说明 会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周 五）15:30-17:00。 届时公司高管将在线就 2025 年半年度业绩等投资者关心的问题，与投资者 进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 ...